Project 4 - Inhibitors of Flavivirus Replication
项目 4 - 黄病毒复制抑制剂
基本信息
- 批准号:10513945
- 负责人:
- 金额:$ 291.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-16 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAfricanAnimal ModelAnimalsAntiviral AgentsBindingBiological AssayBiological TestingBloodBlood - brain barrier anatomyBrainCanadaCell modelCellsChronicCollaborationsContainmentCountryDataDengueDengue VirusDevelopmentDiseaseDoseDrug resistanceEncephalitis VirusesEuropeFlavivirusFlavivirus InfectionsG-QuartetsGenomeGoalsHamstersHumanIn VitroIndividualInfectionJapanese encephalitis virusLeadLibrariesModelingMusNeurologicNeuronsOralOrganoidsPersonsPharmaceutical PreparationsPolymerasePowassan virusPublic HealthRNARNA VirusesReporterResearchResistanceRibonucleosidesSerial PassageSouth AmericanTestingTick-Borne Encephalitis VirusTissuesTreatment EfficacyVaccinationViralViral Load resultVirusWest Nile virusYellow Fever VaccineYellow fever virusZika Virusanaloganti-viral efficacycell typeclinical candidatecytotoxicitydrug developmentexperimental studygenome sequencinggut microbiomehigh throughput screeninghuman stem cellsin vivoin vivo evaluationinhibitormacrophagemeetingsmembermutantpandemic diseasescreeningsmall molecule therapeuticsstem cell differentiationstem cellstherapeutic evaluationtripolyphosphatevaccine accessviral RNAviral resistancewhole genome
项目摘要
Emerging and endemic members of the genus Flavivirus pose significant worldwide public health threats. The
global ranges of dengue viruses, Japanese encephalitis virus, West Nile virus (WNV), tick-borne encephalitis
virus and ZIKV have recently expanded. Dengue virus is estimated to infect ~400 million, cause illness in ~100
million, and kill ~21,000 people a year. Yellow fever virus remains a public health concern in 34 African countries
and 13 South American countries. Newly emerging flaviviruses include Powassan virus (POWV) (northeast US
and Canada) and Usutu virus (Europe). Vaccines are available for humans for only some flaviviruses, but they
are not always used. A few individuals develop multiorgan disease after vaccination with the live 17D yellow
fever vaccine which is typically fatal. There are currently no effective flavivirus-specific small molecule
therapeutics for treatment of humans with flavivirus infections. The goal of the research proposed in Project 4 of
the AC/DC is to develop clinical candidate compounds that can be delivered orally, have broad anti-flavivirus
activity and directly act on a viral component. Under Aim 1, we will develop four ribonucleoside analogs
synthesized by Core
B, for which preliminary data indicating anti-flavivirus activity has already been obtained, by
a reiterative analog synthesis-biological testing strategy with Cores B and C. Compounds will be tested for
antiviral activity against a panel of flaviviruses and cytotoxicity in primary mouse and human macrophages and
neural cells. Mode of action and development of drug resistance will also be analyzed. Under Aim 2, reporter
POWV and WNV viruses will be generated and used in high throughput screening of ~300,000 unique
compounds under BSL3 containment by Core F. Hits validated by counter-screening will be further developed
under Aim 1. Compounds meeting the advancement criteria will be tested for in vivo efficacy in flavivirus mouse
and hamster infection models and in human cortical organoids. The effect of the gut microbiome on the activity
of lead flavivirus antiviral compounds will be assessed in collaboration with Project 7. The impact of antiviral
treatment on acute and chronic virus-induced neurological signatures in POWV and WNV infected animals and
organoids will be evaluated in collaboration with Project 2. Core D will provide whole genome sequencing of viral
mutants generated during viral resistance profiling of lead compounds.
新出现的和流行的黄病毒属成员对世界范围内的公共卫生构成重大威胁。这个
全球范围的登革热病毒、日本脑炎病毒、西尼罗河病毒(WNV)、森林脑炎
病毒和ZIKV最近有所扩大。据估计,登革热病毒感染约4亿人,导致约100人患病
每年杀死约21,000人。黄热病病毒在34个非洲国家仍然是一个公共卫生问题
和13个南美国家。新出现的黄病毒包括鲍瓦桑病毒(POWV)(美国东北部
和Usutu病毒(欧洲)。人类只有一些黄病毒的疫苗可用,但它们
并不总是被使用。少数人在接种活的17D黄牛疫苗后患上多器官疾病
通常致命的发烧疫苗。目前还没有有效的针对黄病毒的小分子
治疗人类感染黄病毒的治疗学。的项目4中提出的研究目标
AC/DC旨在开发可口服、具有广泛抗黄病毒作用的临床候选化合物
并直接作用于病毒成分。在目标1下,我们将开发四个核糖核苷类似物
由Core合成
B,已经获得了表明抗黄病毒活性的初步数据,通过
以B和C为核心的反复模拟合成-生物测试策略将测试化合物
原代小鼠和人巨噬细胞对一组黄病毒的抗病毒活性和细胞毒性
神经细胞。还将对耐药的作用方式和发展进行分析。在Aim 2下,记者
POWV和WNV病毒将被生成并用于高通量筛选~300,000个唯一
经反筛选验证的符合BSL3限制的化合物将得到进一步开发
根据目标1.符合进展标准的化合物将在黄病毒小鼠身上进行体内疗效测试
以及仓鼠感染模型和人类皮质类器官中。肠道微生物群对活性的影响
将与项目7合作评估铅黄病毒抗病毒化合物的影响。
POWV和WNV感染动物急、慢性病毒所致神经症状的治疗
有机化合物将与项目2合作进行评估。核心D将提供病毒的全基因组测序
在先导化合物的病毒抗性分析过程中产生的突变。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Margo A Brinton其他文献
Margo A Brinton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Margo A Brinton', 18)}}的其他基金
Alternative regulation of ISGs in WNV-infected cells
WNV 感染细胞中 ISG 的替代调节
- 批准号:
8385421 - 财政年份:2012
- 资助金额:
$ 291.13万 - 项目类别:
Alternative regulation of ISGs in WNV-infected cells
WNV 感染细胞中 ISG 的替代调节
- 批准号:
8500175 - 财政年份:2012
- 资助金额:
$ 291.13万 - 项目类别:
Functional analysis of flavivirus genetic resistance.
黄病毒遗传抗性的功能分析。
- 批准号:
8068144 - 财政年份:2010
- 资助金额:
$ 291.13万 - 项目类别:
Development of a new model of viral hemorrhagic fever.
病毒性出血热新模型的开发。
- 批准号:
7241848 - 财政年份:2007
- 资助金额:
$ 291.13万 - 项目类别:
Development of a new model of viral hemorrhagic fever.
病毒性出血热新模型的开发。
- 批准号:
7501890 - 财政年份:2007
- 资助金额:
$ 291.13万 - 项目类别:
Analysis of SNPs Associated With WNV-Induced Disease
与西尼罗河病毒引起的疾病相关的 SNP 分析
- 批准号:
6912093 - 财政年份:2004
- 资助金额:
$ 291.13万 - 项目类别:
Analysis of SNPs Associated With WNV-Induced Disease
与西尼罗河病毒引起的疾病相关的 SNP 分析
- 批准号:
7119237 - 财政年份:2004
- 资助金额:
$ 291.13万 - 项目类别:
Oas-1 gene transgenic mice for WNV research.
用于 WNV 研究的 Oas-1 基因转基因小鼠。
- 批准号:
6758238 - 财政年份:2004
- 资助金额:
$ 291.13万 - 项目类别:
Oas-1 gene transgenic mice for WNV research.
用于 WNV 研究的 Oas-1 基因转基因小鼠。
- 批准号:
6876512 - 财政年份:2004
- 资助金额:
$ 291.13万 - 项目类别:
Analysis of SNPs Associated With WNV-Induced Disease
与西尼罗河病毒引起的疾病相关的 SNP 分析
- 批准号:
6953145 - 财政年份:2004
- 资助金额:
$ 291.13万 - 项目类别:
相似海外基金
Tracing the African roots of Sri-Lanka Portuguese
追溯斯里兰卡葡萄牙语的非洲根源
- 批准号:
AH/Z505717/1 - 财政年份:2024
- 资助金额:
$ 291.13万 - 项目类别:
Research Grant
Commercialisation of African Youth Enterprise Programme
非洲青年企业计划商业化
- 批准号:
ES/Y010752/1 - 财政年份:2024
- 资助金额:
$ 291.13万 - 项目类别:
Research Grant
Evaluating the effectiveness and sustainability of integrating helminth control with seasonal malaria chemoprevention in West African children
评估西非儿童蠕虫控制与季节性疟疾化学预防相结合的有效性和可持续性
- 批准号:
MR/X023133/1 - 财政年份:2024
- 资助金额:
$ 291.13万 - 项目类别:
Fellowship
Resilient and Equitable Nature-based Pathways in Southern African Rangelands (REPAiR)
南部非洲牧场弹性且公平的基于自然的途径 (REPAiR)
- 批准号:
NE/Z503459/1 - 财政年份:2024
- 资助金额:
$ 291.13万 - 项目类别:
Research Grant
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 291.13万 - 项目类别:
Research Grant
Understanding differences in host responses to African swine fever virus
了解宿主对非洲猪瘟病毒反应的差异
- 批准号:
BB/Z514457/1 - 财政年份:2024
- 资助金额:
$ 291.13万 - 项目类别:
Fellowship
The impact on human health of restoring degraded African drylands
恢复退化的非洲旱地对人类健康的影响
- 批准号:
MR/Y019806/1 - 财政年份:2024
- 资助金额:
$ 291.13万 - 项目类别:
Research Grant
CAREER: Habitability of the Hadean Earth - A South African perspective
职业:冥古宙地球的宜居性——南非的视角
- 批准号:
2336044 - 财政年份:2024
- 资助金额:
$ 291.13万 - 项目类别:
Continuing Grant
Nowcasting with Artificial Intelligence for African Rainfall: NAIAR
利用人工智能预测非洲降雨量:NAIAR
- 批准号:
NE/Y000420/1 - 财政年份:2024
- 资助金额:
$ 291.13万 - 项目类别:
Research Grant
Assessing the role of the lithospheric mantle during passive margin development - insights from the South Atlantic African margin
评估岩石圈地幔在被动边缘发育过程中的作用 - 来自南大西洋非洲边缘的见解
- 批准号:
2305552 - 财政年份:2024
- 资助金额:
$ 291.13万 - 项目类别:
Standard Grant